Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis
We sought to determine the prevalence of antiphospholipid antibodies (aPLs) and their correlation with COVID-19 severity (in terms of clinical and laboratory parameters) in patients without thrombotic events during the early phase of infection. This was a cross-sectional study with the inclusion of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/5/1241 |
| _version_ | 1797600942413053952 |
|---|---|
| author | Alina Dima Daniela Nicoleta Popescu Ruxandra Moroti Elisabeta Stoica Georgiana State Florentina Negoi Ioana Adriana Berza Magda Parvu |
| author_facet | Alina Dima Daniela Nicoleta Popescu Ruxandra Moroti Elisabeta Stoica Georgiana State Florentina Negoi Ioana Adriana Berza Magda Parvu |
| author_sort | Alina Dima |
| collection | DOAJ |
| description | We sought to determine the prevalence of antiphospholipid antibodies (aPLs) and their correlation with COVID-19 severity (in terms of clinical and laboratory parameters) in patients without thrombotic events during the early phase of infection. This was a cross-sectional study with the inclusion of hospitalized COVID-19 patients from a single department during the COVID-19 pandemic (April 2020–May 2021). Previous known immune disease or thrombophilia along with long-term anticoagulation and patients with overt arterial or venous thrombosis during SARS-CoV-2 infection were excluded. In all cases, data on four criteria for aPL were collected, namely lupus anticoagulant (LA), IgM and IgG anticardiolipin antibodies (aCL), as well as IgG anti-β2 glycoprotein I antibodies (aβ2GPI). One hundred and seventy-nine COVID-19 patients were included, with a mean age of 59.6 (14.5) years and a sex ratio of 0.8 male: female. LA was positive in 41.9%, while it was strongly positive in 4.5%; aCL IgM was found in 9.5%, aCL IgG in 4.5%, and aβ2GPI IgG in 1.7% of the sera tested. Clinical correlation: LA was more frequently expressed in severe COVID-19 cases than in moderate or mild cases (<i>p</i> = 0.027). Laboratory correlation: In univariate analysis, LA levels were correlated with D-dimer (<i>p</i> = 0.016), aPTT (<i>p</i> = 0.001), ferritin (<i>p</i> = 0.012), C-reactive protein (CRP) (<i>p</i> = 0.027), lymphocyte (<i>p</i> = 0.040), and platelet (<i>p</i> < 0.001) counts. However, in the multivariate analysis, only the CRP levels correlated with LA positivity: OR (95% CI) 1.008 (1.001–1.016), <i>p</i> = 0.042. LA was the most common aPL identified in the acute phase of COVID-19 and was correlated with infection severity in patients without overt thrombosis. |
| first_indexed | 2024-03-11T03:55:56Z |
| format | Article |
| id | doaj.art-a1911996474e472b8560085401f9ae4d |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T03:55:56Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-a1911996474e472b8560085401f9ae4d2023-11-18T00:34:06ZengMDPI AGBiomedicines2227-90592023-04-01115124110.3390/biomedicines11051241Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt ThrombosisAlina Dima0Daniela Nicoleta Popescu1Ruxandra Moroti2Elisabeta Stoica3Georgiana State4Florentina Negoi5Ioana Adriana Berza6Magda Parvu7Department of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, RomaniaDepartment of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, RomaniaDepartment of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, RomaniaDepartment of Infectious Diseases, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, RomaniaDepartment of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, RomaniaDepartment of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, RomaniaDepartment of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, RomaniaDepartment of Rheumatology, Colentina Clinical Hospital, 020125 Bucharest, RomaniaWe sought to determine the prevalence of antiphospholipid antibodies (aPLs) and their correlation with COVID-19 severity (in terms of clinical and laboratory parameters) in patients without thrombotic events during the early phase of infection. This was a cross-sectional study with the inclusion of hospitalized COVID-19 patients from a single department during the COVID-19 pandemic (April 2020–May 2021). Previous known immune disease or thrombophilia along with long-term anticoagulation and patients with overt arterial or venous thrombosis during SARS-CoV-2 infection were excluded. In all cases, data on four criteria for aPL were collected, namely lupus anticoagulant (LA), IgM and IgG anticardiolipin antibodies (aCL), as well as IgG anti-β2 glycoprotein I antibodies (aβ2GPI). One hundred and seventy-nine COVID-19 patients were included, with a mean age of 59.6 (14.5) years and a sex ratio of 0.8 male: female. LA was positive in 41.9%, while it was strongly positive in 4.5%; aCL IgM was found in 9.5%, aCL IgG in 4.5%, and aβ2GPI IgG in 1.7% of the sera tested. Clinical correlation: LA was more frequently expressed in severe COVID-19 cases than in moderate or mild cases (<i>p</i> = 0.027). Laboratory correlation: In univariate analysis, LA levels were correlated with D-dimer (<i>p</i> = 0.016), aPTT (<i>p</i> = 0.001), ferritin (<i>p</i> = 0.012), C-reactive protein (CRP) (<i>p</i> = 0.027), lymphocyte (<i>p</i> = 0.040), and platelet (<i>p</i> < 0.001) counts. However, in the multivariate analysis, only the CRP levels correlated with LA positivity: OR (95% CI) 1.008 (1.001–1.016), <i>p</i> = 0.042. LA was the most common aPL identified in the acute phase of COVID-19 and was correlated with infection severity in patients without overt thrombosis.https://www.mdpi.com/2227-9059/11/5/1241antiphospholipid syndromecriteria antiphospholipid antibodieslupus anticoagulantC-reactive proteinCOVID-19 severitySARS-CoV-2 |
| spellingShingle | Alina Dima Daniela Nicoleta Popescu Ruxandra Moroti Elisabeta Stoica Georgiana State Florentina Negoi Ioana Adriana Berza Magda Parvu Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis Biomedicines antiphospholipid syndrome criteria antiphospholipid antibodies lupus anticoagulant C-reactive protein COVID-19 severity SARS-CoV-2 |
| title | Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis |
| title_full | Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis |
| title_fullStr | Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis |
| title_full_unstemmed | Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis |
| title_short | Antiphospholipid Antibodies Occurrence in Acute SARS-CoV-2 Infection without Overt Thrombosis |
| title_sort | antiphospholipid antibodies occurrence in acute sars cov 2 infection without overt thrombosis |
| topic | antiphospholipid syndrome criteria antiphospholipid antibodies lupus anticoagulant C-reactive protein COVID-19 severity SARS-CoV-2 |
| url | https://www.mdpi.com/2227-9059/11/5/1241 |
| work_keys_str_mv | AT alinadima antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis AT danielanicoletapopescu antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis AT ruxandramoroti antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis AT elisabetastoica antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis AT georgianastate antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis AT florentinanegoi antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis AT ioanaadrianaberza antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis AT magdaparvu antiphospholipidantibodiesoccurrenceinacutesarscov2infectionwithoutovertthrombosis |